NovaBay Pharmaceuticals Reports Material Events
Ticker: NBY · Form: 8-K · Filed: Aug 19, 2025 · CIK: 1389545
Sentiment: neutral
Topics: material-agreement, equity-sale, corporate-governance, filing-update
TL;DR
NovaBay dropped an 8-K detailing major corporate moves - new deals, stock sales, exec changes, and bylaw tweaks.
AI Summary
NovaBay Pharmaceuticals, Inc. filed an 8-K on August 19, 2025, reporting several material events. These include entering into a definitive agreement, unregistered sales of equity securities, and modifications to security holder rights. The filing also details the departure of directors or officers, election of directors, appointment of officers, and compensatory arrangements. Additionally, amendments to articles of incorporation or bylaws and changes in the fiscal year were noted, alongside other events and financial statements.
Why It Matters
This 8-K filing signals significant corporate actions and potential changes in the company's structure, governance, and financial arrangements that could impact investors.
Risk Assessment
Risk Level: medium — The filing covers multiple significant events including material definitive agreements and unregistered equity sales, which can introduce uncertainty and risk.
Key Players & Entities
- NovaBay Pharmaceuticals, Inc. (company) — Registrant
- August 19, 2025 (date) — Date of earliest event reported
FAQ
What specific material definitive agreement did NovaBay Pharmaceuticals enter into?
The filing indicates the entry into a material definitive agreement, but the specific details of this agreement are not provided in the provided text.
What type of equity securities were sold in the unregistered sale?
The filing states there was an unregistered sale of equity securities, but the specific type and amount are not detailed in the provided text.
Were there any changes to NovaBay's board of directors or executive officers?
Yes, the filing reports the departure of directors or certain officers, the election of directors, and the appointment of certain officers.
Did NovaBay Pharmaceuticals amend its articles of incorporation or bylaws?
Yes, the filing indicates amendments to articles of incorporation or bylaws were made.
What is NovaBay Pharmaceuticals' fiscal year end?
NovaBay Pharmaceuticals' fiscal year ends on December 31st.
Filing Stats: 4,683 words · 19 min read · ~16 pages · Grade level 16.1 · Accepted 2025-08-19 17:29:08
Key Financial Figures
- $0.01 — ch Registered Common Stock, par value $0.01 per share NBY NYSE American Indic
- $3.85 million — ar value $0.01 (the "Common Stock") for $3.85 million and (ii) an aggregate of 268,750 shares
- $2.15 million — res") of Common Stock for an additional $2.15 million (collectively, the "Investment"). The s
- $8.00 — ed Stock from the Company at a price of $8.00 per share for aggregate gross proceeds
- $0 — k on the day of the Second Meeting plus $0.02, provided, that the number of shares
- $175,000 — rant Holders and (ii) a cash payment of $175,000 to each of the Remaining Warrant Holder
- $525,000 — ning Warrant Holder, or an aggregate of $525,000 for all shares of Series F Preferred St
- $0.80 — ted Special Dividend to equal or exceed $0.80 per share (prior to any stock split, sh
Filing Documents
- novabay_8k.htm (8-K) — 131KB
- novabay_ex3-1.htm (EX-3.1) — 107KB
- novabay_ex3-2.htm (EX-3.2) — 106KB
- novabay_ex3-3.htm (EX-3.3) — 39KB
- novabay_ex10-1.htm (EX-10.1) — 226KB
- novabay_ex10-2.htm (EX-10.2) — 68KB
- novabay_ex10-3.htm (EX-10.3) — 71KB
- novabay_ex10-4.htm (EX-10.4) — 69KB
- novabay_ex10-5.htm (EX-10.5) — 48KB
- novabay_ex10-6.htm (EX-10.6) — 41KB
- novabay_ex10-7.htm (EX-10.7) — 83KB
- novabay_ex10-8.htm (EX-10.8) — 35KB
- novabay_ex10-9.htm (EX-10.9) — 23KB
- novabay_ex99-1.htm (EX-99.1) — 10KB
- ex10-6_001.jpg (GRAPHIC) — 7KB
- ex10-8_001.jpg (GRAPHIC) — 7KB
- ex99-1_001.jpg (GRAPHIC) — 7KB
- 0001829126-25-006520.txt ( ) — 1509KB
- nby-20250819.xsd (EX-101.SCH) — 3KB
- nby-20250819_lab.xml (EX-101.LAB) — 33KB
- nby-20250819_pre.xml (EX-101.PRE) — 22KB
- novabay_8k_htm.xml (XML) — 4KB
01
Item 1.01 Entry into a Material Definitive Agreement. Overview NovaBay Pharmaceuticals, Inc. (the "Company") has been continuing to explore and evaluate strategic options available to the Company to maximize its value following the sale of the Company's eyecare products sold under the Avenova brand and related assets to PRN Physician Recommended Nutriceuticals, LLC on January 17, 2025. Among these strategic options, the Company has been pursuing potential strategic transactions, including investments, mergers, reverse mergers, strategic partnerships, licensing and sub-licensing transactions. The Company also has the option to pursue a voluntary liquidation and dissolution under Delaware law (the "Dissolution") pursuant to the Plan of Complete Liquidation and Dissolution of the Company that stockholders approved at the Company's special meeting of stockholders held on April 16, 2025. Although stockholder approval of the Dissolution was received, the Board of Directors (the "Board") was authorized to subsequently determine, in its discretion, whether or not to proceed with the Dissolution. Accordingly, the Board retained complete discretion to evaluate and determine if and when the Dissolution should be effected or if another strategic option would be a better opportunity to maximize the remaining value of the Company for its stockholders. Following the Company's review of its strategic options, the Company determined that pursuing a strategic investment transaction that provides for a Special Dividend and a Post-Investment Transaction (both as defined below), instead of pursuing the Dissolution, is in the best interest of the Company and its stockholders at this time. On August 19, 2025, the Company entered into a Securities Purchase Agreement (the "Purchase Agreement") with David E. Lazar, an Israeli and E.U. citizen residing in Panama, that provides for the Company to sell in a private placement (i) an aggregate of 481,250 shares of Series D non-voting conver